<DOC>
	<DOCNO>NCT00906880</DOCNO>
	<brief_summary>Multicenter , open label , uncontrolled phase IIIb study therapeutic use combination nifurtimox eflornithine ( NECT ) treatment Trypanosoma brucei gambiense human African trypanosomiasis ( HAT ) meningo-encephalitic phase . Overall objective : Assess clinical tolerability , feasibility effectiveness NECT co-administration treat patient T.b . gambiense human African trypanosomiasis ( HAT ) meningo-encephalitic phase actual real-life condition ( regular treatment center National HAT Control Programme , NGO treatment center ) . Primary objective : - Assess clinical response NECT co-administration field condition . Secondary objective : - Assess incidence type adverse event ( AE ) , capacity treatment center deal . - Assess feasibility implementation NECT coadministration health center . - Assess effectiveness NECT co-administration 24* month treatment .</brief_summary>
	<brief_title>Clinical Study Assess Tolerability , Feasibility Effectiveness Nifurtimox Eflornithine ( NECT ) Treatment Trypanosoma Brucei Gambiense Human African Trypanosomiasis ( HAT ) Meningo-encephalitic Phase</brief_title>
	<detailed_description />
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>All patient diagnose stage 2 HAT accord diagnostic protocol use treatment center ( generally , presence parasite blood , lymph node fluid CSF elevate white blood cell count CSF , vary center center ) include write Informed Consent give patient legally acceptable representative patient minor unable communicate . Pregnancy breastfeed woman : On case case basis accord guideline National HAT Control Programme NGO , Investigator decide treat patient defer treatment . In case inclusion , motherchild pair child lactate mother closely monitor treatment follow . Children 2 year age : On case case basis , Investigator decide treat infant NECT alternative treatment ( preferably eflornithine ) . In case inclusion , infant closely monitor treatment follow like child le 12 year age . Unable take oral medication , impossibility use nasogastric tube . Treatment failure nifurtimoxeflornithine treatment . Any condition reason Investigator ( responsible treat staff member ) judge another HAT treatment warrant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Human African Trypanosomiasis</keyword>
	<keyword>HAT</keyword>
	<keyword>sleep sickness</keyword>
	<keyword>combination treatment</keyword>
	<keyword>nifurtimox</keyword>
	<keyword>eflornithine</keyword>
	<keyword>Human African Trypanosomiasis meningo-encephalitic phase ( stage 2 HAT )</keyword>
</DOC>